Quoin制药有限公司 (QNRX)在2023年第四季度财报电话会议后股价出现明显波动,公司详细介绍了财务表现、战略发展和未来展望。该股在前一交易日下跌6.45%后,盘前上涨2.08%。主要亮点包括大量现金储备、净亏损减少以及临床试验的进展。

Quoin Pharmaceuticals Ltd. (QNRX), a specialty pharmaceutical company currently valued at $2.42 million, announced today the initiation of the "NETHERTON NOW" campaign aimed at increasing awareness of ...

ASHBURN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty ...

Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan ...

Quoin Pharmaceuticals (QNRX) announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome. In December 2024 and January 2025, Quoin announced data from the mid ...

And that’s exactly what Harrisburg did, making eight shots from 3-point range in a 53-33 win over Benton in its semifinal ...

City officials say the order will be lifted as soon as the Illinois Environmental Protection Agency approves water tests. The ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.